IGM Biosciences Inc (NASDAQ: IGMS) has experienced a decline in its stock price by -6.96 compared to its previous closing price of 1.58. However, the company has seen a fall of -13.53% in its stock price over the last five trading days. prnewswire.com reported 2025-01-28 that NEW YORK, Jan. 28, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. (“IGM” or the “Company”) (NASDAQ: IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Is It Worth Investing in IGM Biosciences Inc (NASDAQ: IGMS) Right Now?
Additionally, the 36-month beta value for IGMS is -0.00. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 10 rating it as “hold,” and 1 rating it as “sell.”
The public float for IGMS is 17.59M and currently, short sellers hold a 11.14% ratio of that float. The average trading volume of IGMS on January 30, 2025 was 453.12K shares.
IGMS’s Market Performance
IGMS stock saw a decrease of -13.53% in the past week, with a monthly decline of -77.89% and a quarterly a decrease of -91.27%. The volatility ratio for the week is 7.69%, and the volatility levels for the last 30 days are 11.23% for IGM Biosciences Inc (IGMS). The simple moving average for the past 20 days is -56.21% for IGMS’s stock, with a -85.12% simple moving average for the past 200 days.
Analysts’ Opinion of IGMS
Many brokerage firms have already submitted their reports for IGMS stocks, with Stifel repeating the rating for IGMS by listing it as a “Hold.” The predicted price for IGMS in the upcoming period, according to Stifel is $2.50 based on the research report published on January 10, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see IGMS reach a price target of $1.50, previously predicting the price at $20. The rating they have provided for IGMS stocks is “Sector Perform” according to the report published on January 10th, 2025.
Morgan Stanley gave a rating of “Underweight” to IGMS, setting the target price at $2 in the report published on January 10th of the current year.
IGMS Trading at -77.69% from the 50-Day Moving Average
After a stumble in the market that brought IGMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.47% of loss for the given period.
Volatility was left at 11.23%, however, over the last 30 days, the volatility rate increased by 7.69%, as shares sank -76.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -86.82% lower at present.
During the last 5 trading sessions, IGMS fell by -13.53%, which changed the moving average for the period of 200-days by -82.42% in comparison to the 20-day moving average, which settled at $3.3568. In addition, IGM Biosciences Inc saw -75.94% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IGMS starting from Weber Steven, who sale 1,122 shares at the price of $1.70 back on Jan 15 ’25. After this action, Weber Steven now owns 30,582 shares of IGM Biosciences Inc, valued at $1,907 using the latest closing price.
Weber Steven, the PRINCIPAL ACCOUNTING OFFICER of IGM Biosciences Inc, sale 539 shares at $7.48 during a trade that took place back on Dec 16 ’24, which means that Weber Steven is holding 31,704 shares at $4,032 based on the most recent closing price.
Stock Fundamentals for IGMS
Current profitability levels for the company are sitting at:
- -80.44 for the present operating margin
- -1.27 for the gross margin
The net margin for IGM Biosciences Inc stands at -75.34. The total capital return value is set at -0.9. Equity return is now at value -132.11, with -56.45 for asset returns.
Based on IGM Biosciences Inc (IGMS), the company’s capital structure generated 0.37 points at debt to capital in total, while cash flow to debt ratio is standing at -3.62. The debt to equity ratio resting at 0.58. The interest coverage ratio of the stock is -59.0.
Currently, EBITDA for the company is -253.36 million with net debt to EBITDA at -0.01. When we switch over and look at the enterprise to sales, we see a ratio of 30.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.22.
Conclusion
In conclusion, IGM Biosciences Inc (IGMS) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
